However, other experimental findings seem to converge towards a useful application of the purinergic receptor modulation in salivary gland dysfunction, which is usually observed in the Sjögren’s syndrome (SS) and as a consequence of radiotherapy (RT) used for treating head and neck cancer (HNC). Here, P2RX4 is linked to synovial sarcoma.